Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Change in Accured Expenses: 2017-2024

Historic Change in Accured Expenses for Solid Biosciences (SLDB) over the last 8 years, with Dec 2024 value amounting to $1.6 million.

  • Solid Biosciences' Change in Accured Expenses rose 198.72% to $1.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $4.8 million, marking a year-over-year increase of 168.41%. This contributed to the annual value of $4.8 million for FY2024, which is 168.41% up from last year.
  • As of Q4 2024, Solid Biosciences' Change in Accured Expenses stood at $1.6 million, which was down 50.92% from $3.3 million recorded in Q3 2024.
  • Over the past 5 years, Solid Biosciences' Change in Accured Expenses peaked at $8.7 million during Q2 2022, and registered a low of -$5.0 million during Q3 2022.
  • Moreover, its 3-year median value for Change in Accured Expenses was -$83,500 (2024), whereas its average is $302,583.
  • Over the last 5 years, Solid Biosciences' Change in Accured Expenses had its largest YoY gain of 1,515.01% in 2022, and its largest YoY loss of 1,544.37% in 2022.
  • Over the past 5 years, Solid Biosciences' Change in Accured Expenses (Quarterly) stood at $887,000 in 2020, then surged by 190.42% to $2.6 million in 2021, then dropped by 0.27% to $2.6 million in 2022, then crashed by 164.03% to -$1.6 million in 2023, then skyrocketed by 198.72% to $1.6 million in 2024.
  • Its Change in Accured Expenses stands at $1.6 million for Q4 2024, versus $3.3 million for Q3 2024 and -$380,000 for Q2 2024.